All In Biotech

Drug Trial Radar · NCT04874948

Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment

A Single-Center, Open Label Study to Investigate the Mass Balance, Excretion Pathways and Metabolites After a Single Oral Dose of 500 MG, 3.7 MBq, [14C]BTZ-043 in Healthy Male Volunteers

Last checked: Nov 19, 2026Latest source record: Dec 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

4

Actual

Start

Oct 8, 2021

Primary completion

Oct 15, 2021

Study completion Nov 9, 2021

Sponsor

Lead sponsor
Michael HoelscherAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institute
First posted
May 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a Phase 1, single-center, open-label study to investigate the absorption, metabolism, and excretion of BTZ-043 after a single oral administration of 500 mg BTZ-043 containing 3.7 MBq of \[14C\]BTZ-043 in 4 healthy adult male subjects

Conditions

  • Tuberculosis
  • Tuberculosis, Pulmonary
  • Bacterial Infections Respiratory
  • Lung Diseases
  • Mycobacterium Infections

Interventions

  • 500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043Drug

    Single oral administration of 14C-labeled radioactive 500mg BTZ-043

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rates and Routes of ExcretionTime frame: Urine and faeces were collected from the administration of the study medication until cumulative excretion reached 90% of total radioactivity administered. This was achieved by all subjects after 168 hours.
  2. Pharmacokinetics of Total Radioactivity in Blood and Plasma (Cmax)Time frame: Blood samples for total radioactivity were collected from day 1 until 168 h post dosing
  3. Pharmacokinetics of Total Radioactivity in Blood and Plasma (AUC-t)Time frame: Blood samples for total radioactivity were collected from day 1 until 168 h post dosing
  4. Pharmacokinetics of Total Radioactivity in Blood (T1/2)Time frame: Blood samples for total radioactivity were collected from day 1 until 168 h post dosing
  5. Pharmacokinetics of Total Radioactivity in Plasma (T1/2)Time frame: Blood samples for total radioactivity were collected from day 1 until 168 h post dosing
  6. Plasma PK of BTZ-043 and Main Metabolites (Cmax)Time frame: Day 1 to Day 3
  7. Plasma PK of BTZ-043 and Main Metabolites (AUC-last)Time frame: Day 1 to Day 3
  8. Plasma PK of BTZ-043 and Main Metabolites (t1/2)Time frame: Day 1 to Day 3
  9. Urine Concentrations of BTZ-043 and Main MetabolitesTime frame: Assessed from time of dosing up to 168 h post dose. BTZ-043 and metabolites were excreted fom 0 - 24 h (BTZ-043 and M1) and from 0 - 48 h (M2, M4 total and M10 total).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PRA Health Sciences (PRA) - Early Development Services (EDS)

    Groningen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.